1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Technology appraisal guidance [TA170] Published: 22 April 2009

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members, guideline representatives and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

6 Recommendations for further research

6 Recommendations for further research

6.1 Further head-to-head trials of rivaroxaban compared with enoxaparin and dabigatran in both total hip replacement and total knee replacement would be useful to strengthen the evidence base for this comparison.

  • National Institute for Health and Care Excellence (NICE)

  • Next